Australia's Leading Ophthalmic Magazine Since 1975

     Free Sign Up     

Australia's Leading Ophthalmic Magazine Since 1975

     Free Sign Up     

Mobile app allows patients to monitor AMD from home

Swiss technology company Oculocare Medical has developed a mobile app that allows patients with age-related macular degeneration (AMD) to monitor their condition from home.

Alleye recently received a USFDA 510K clearance for use in the detection and monitoring of AMD and is designed to detect and characterise central and paracentral metamorphopsia (visual distortion) in patients with macular conditions including AMD and diabetic retinopathy.

Alleye's AMD monitoring app

After medical diagnosis by an eye specialist, Alleye lets patients regularly perform simple self-tests at home to monitor their eyesight and/or assess disease progression.

“We are very excited about the FDA clearance which will help millions of patients with AMD to better manage their health by monitoring their eyesight,” Oculocare CEO and co-founder Mr Lucas Bachmann said.

“We are committed to advancing medical software innovations that leverage digital technology to improve patient care. After Europe, we plan to make Alleye available in the US and other countries worldwide.”

Alleye was developed to allow patients to regularly and independently test their eyesight, and its framework has been analysed in five scientific studies in which several hundred subjects made over 25,000 measurements.

large leaderboard

Younger Optics
Editor's Suggestion
Hot Stories

Insight Magazine


Subscribe for Insight in your Inbox

Get Insight with the latest in industry news, trends, new products, services and equipment!